Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study

Thoracic Cancer

Volumn 7, Issue 4, 2016, Pages 428-436

  Pu, Dan ^a   Liang, Hao ^a   Wei, Fang ^b   Akin, David ^b   Feng, Ziding ^c   Yan, QingXiang ^c   Li, Yin ^d   Zhen, Yan ^d   Xu, Lin ^e   Dong, Gaochao ^e   Wan, Huajing ^f   Dong, Jingsi ^a   Qiu, Xiaoming ^a   Qin, Changlong ^a   Zhu, Daxing ^a   Wang, Xi ^a   Sun, Tong ^a   Zhang, Wenbiao ^a   Li, Canjun ^a   Tang, Xiaojun ^a   Qiao, Youlin ^g   Wong, David T W ^b   Zhou, Qinghua ^a   more..

^a SICHUAN UNIVERSITY   (China)

^b UCLA SCHOOL OF DENTISTRY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ZHENGZHOU UNIVERSITY   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

^g PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

EGFR mutation; liquid biopsy; lung cancer; saliva diagnostics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EGFR GENE; ELECTRIC FIELD; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FEMALE; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PILOT STUDY; PRIORITY JOURNAL; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

EID: 84990236512     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12350     Document Type: Article

References (29)

1. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014; 2 (7): 61.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
3. Sueoka-Aragane N, Katakami N, Satouchi M et al. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci 2015; 107: 162–7.
4. Seki Y, Fujiwara Y, Kohno T et al. Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors. Oncologist 2016; 21: 156–64.
5. Cohen V, Agulnik JS, Jarry J et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer 2006; 107: 2858–65.
6. Kawahara A, Fukumitsu C, Taira T et al. Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings. Cancer Cytopathol 2015; 123: 620–8.
7. Uchida J, Kato K, Kukita Y et al. Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem 2015; 61: 1191–6.
8. Qian X, Wang S, Shen Y et al. [Methodology comparison and influence factors analysis of epidermal growth factor receptor mutation detection]. Zhonghua Yi Xue Za Zhi 2015; 95: 106–11. (In Chinese.).
9. Xu H, Sun W, Zhang G, Cheng Y. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens. J BUON 2015; 20 (1): 142–5.
10. Zhu G, Ye X, Dong Z et al. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J Mol Diagn 2015; 17: 265–72.
11. Lewandowska MA, Czubak K, Klonowska K, Jozwicki W, Kowalewski J, Kozlowski P. The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer. PLoS one 2015; 10 (2): e0117983.
12. Lin J, Gu Y, Du R, Deng M, Lu Y, Ding Y. Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing. Int J Clin Exp Pathol 2014; 7: 8813–22.
13. Takata M, Chikumi H, Matsunami K et al. A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncol Rep 2015; 33: 1040–8.
14. Romanus D, Cardarella S, Cutler D, Landrum MB, Lindeman NI, Gazelle GS. Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J Thorac Oncol 2015; 10: 586–94.
15. Lozano MD, Labiano T, Echeveste J et al. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer. Cancer Cytopathol 2015; 123: 230–6.
16. Tseng JS, Yang TY, Tsai CR et al. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 2015; 10: 603–10.
17. Scarpino S, Pulcini F, Di Napoli A, Giubettini M, Ruco L. EGFR mutation testing in pulmonary adenocarcinoma: Evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies. Lung Cancer 2015; 87: 8–13.
18. Sueoka-Aragane N, Sato A, Kobayashi N et al. Correlation between plasma DNA and tumor status in an animal model. PLoS One 2014; 9 (12): e111881.
19. Deeb KK, Hohman CM, Risch NF, Metzger DJ, Starostik P. Routine clinical mutation profiling of non-small cell lung cancer using next-generation sequencing. Arch Pathol Lab Med 2015; 139: 913–21.
20. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.
21. Niu FY, Wu YL. Novel agents and strategies for overcoming EGFR TKIs resistance. Exp Hematol Oncol 2014; 3: 2.
22. Wei F, Lin CC, Joon A et al. Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. Am J Respir Crit Care Med 2014; 190: 1117–26.
23. Skog J, Würdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biol 2008; 10: 1470–6.
24. Li Y, St John MA, Zhou X et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004; 10: 8442–50.
25. Kimura H, Ohira T, Uchida O et al. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer 2014; 83: 329–33.
26. Sandri MT, Zorzino L, Cassatella MC et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 2010; 17: 1539–45.
27. Biggers B, Knox S, Grant M et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: Preliminary results of a pilot study. Ann Surg Oncol 2009; 16: 969–71.
28. Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: A literature review of clinical reports. J Thorac Dis 2011; 3: 10–8.
29. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2 (3): e73.